CN115427056A - 使用actriib配体陷阱和菲卓替尼治疗贫血的方法 - Google Patents

使用actriib配体陷阱和菲卓替尼治疗贫血的方法 Download PDF

Info

Publication number
CN115427056A
CN115427056A CN202180028593.0A CN202180028593A CN115427056A CN 115427056 A CN115427056 A CN 115427056A CN 202180028593 A CN202180028593 A CN 202180028593A CN 115427056 A CN115427056 A CN 115427056A
Authority
CN
China
Prior art keywords
subject
ligand trap
actriib ligand
seq
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028593.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·拉德姆
S·瑞特兰
J·T·巴克斯托姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN115427056A publication Critical patent/CN115427056A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180028593.0A 2020-04-13 2021-04-12 使用actriib配体陷阱和菲卓替尼治疗贫血的方法 Pending CN115427056A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009400P 2020-04-13 2020-04-13
US63/009,400 2020-04-13
PCT/US2021/026816 WO2021211418A1 (en) 2020-04-13 2021-04-12 Methods for treating anemia using an actriib ligand trap and fedratinib

Publications (1)

Publication Number Publication Date
CN115427056A true CN115427056A (zh) 2022-12-02

Family

ID=78085002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028593.0A Pending CN115427056A (zh) 2020-04-13 2021-04-12 使用actriib配体陷阱和菲卓替尼治疗贫血的方法

Country Status (10)

Country Link
US (1) US20230181690A1 (https=)
EP (1) EP4135736A4 (https=)
JP (1) JP2023523568A (https=)
KR (1) KR20230003502A (https=)
CN (1) CN115427056A (https=)
AU (1) AU2021256419A1 (https=)
BR (1) BR112022020628A2 (https=)
IL (1) IL297258A (https=)
MX (1) MX2022012610A (https=)
WO (1) WO2021211418A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016090077A1 (en) * 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
WO2016183280A1 (en) * 2015-05-13 2016-11-17 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
US20180050085A1 (en) * 2016-07-27 2018-02-22 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
CN109922821A (zh) * 2016-10-20 2019-06-21 马萨诸塞州渤健公司 使用新型杂合actriib配体陷阱蛋白治疗肌肉萎缩和骨病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
PT3286206T (pt) * 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
WO2018053142A2 (en) * 2016-09-14 2018-03-22 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
HRP20241477T1 (hr) * 2017-06-14 2025-01-03 Celgene Corporation Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom
KR20210047308A (ko) * 2018-08-21 2021-04-29 시에라 온코로지, 인코퍼레이티드 골수섬유증을 치료하는 혈소판 수-불특정 방법
EP3856189A4 (en) * 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016090077A1 (en) * 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
WO2016183280A1 (en) * 2015-05-13 2016-11-17 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
US20180050085A1 (en) * 2016-07-27 2018-02-22 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
CN109922821A (zh) * 2016-10-20 2019-06-21 马萨诸塞州渤健公司 使用新型杂合actriib配体陷阱蛋白治疗肌肉萎缩和骨病的方法

Also Published As

Publication number Publication date
MX2022012610A (es) 2022-11-07
EP4135736A1 (en) 2023-02-22
JP2023523568A (ja) 2023-06-06
AU2021256419A1 (en) 2022-10-20
KR20230003502A (ko) 2023-01-06
IL297258A (en) 2022-12-01
WO2021211418A1 (en) 2021-10-21
EP4135736A4 (en) 2024-06-26
US20230181690A1 (en) 2023-06-15
BR112022020628A2 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
AU2021258087B2 (en) Treatment of beta-thalassemia using ActRII ligand traps
AU2021212084B2 (en) Activin-ActRII antagonists and uses for treating anemia
CN111050770A (zh) 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
KR20150038297A (ko) 아플리베르셉트 또는 지브-아플리베르셉트를 포함하는 제조 물품
JP2023508047A (ja) Ｉｌ－２受容体作動薬及び免疫チェックポイント阻害薬を使用する併用療法
CN115427056A (zh) 使用actriib配体陷阱和菲卓替尼治疗贫血的方法
JP2022502411A (ja) 非小細胞肺がんの処置のためのａｘｌ特異的抗体
CN115551487A (zh) 使用ACTRIIB配体陷阱和mTOR抑制剂治疗贫血的方法和组合物
CN110522909A (zh) 一种协同增强抗her2阳性肿瘤效果的药物组合
CN112118858A (zh) 用于未经治疗对象中癌症治疗的靶向tgf-β抑制的给药方案
HK40077393A (en) Methods for treating anemia using an actriib ligand trap and fedratinib
CN112673020A (zh) 用于治疗胆道癌的靶向TGF-β抑制的给药方案
EA049358B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ АНЕМИИ С ПРИМЕНЕНИЕМ ЛИГАНДОВ-ЛОВУШЕК ActRIIB И ИНГИБИТОРОВ mTOR
RU2837724C2 (ru) Способ комбинаторной терапии при лечении миелопролиферативных новообразований конъюгатом дифтерийного токсина с интерлейкином-3 человека в комбинации с другими агентами
HK40049078A (en) Dosing regimens for targeted tgf-β inhibition for use in treating biliary tract cancer
HK40012523A (en) DOSING REGIMENS AND DOSAGE FORMS FOR TARGETED TGF-β INHIBITION
HK1248807B (zh) 激活素-actrii拮抗剂及用於治疗贫血症的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077393

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination